The process of treatment for breast cancer patients is that all patients who can be operated are first treated with surgery; patients with more advanced localization can be treated with neoadjuvant therapy before surgery. After surgery, adjuvant therapy is needed to prevent recurrence and metastasis, and some of these patients can survive for a long time while others are still not immune to failure. After achieving complete remission (CR), the effective treatment regimen should be repeated for consolidation for a second long-term disease-free survival; the other outcome is that the tumor is not controlled, including partial remission (PR), and a new round of treatment has to be done. The difficulty of recurrent treatment is greater than the initial treatment; the more times of recurrent treatment, the less chance of successful treatment, so the initial treatment after recurrent metastasis is critical, must be reasonable and must be fully in place. Breast cancer chemotherapy and endocrine therapy can be used for four kinds of treatment, which can be divided into two types of cases: one is treatment with lesions and the other is treatment without specific lesions, and they are evaluated by different pathways. Preoperative neoadjuvant therapy and relief therapy after recurrent metastases are treatments with lesions. This treatment can be judged efficacy patient by patient or even lesion by lesion. The main expressions of recent efficacy are CR, PR, and recently the addition of TTP, TTF has been proposed for evaluation. Patients without lesions are treated with postoperative adjuvant therapy and post-CR sclerosant therapy. Because there is no longer a specific lesion, only their long-term results can be seen, and only collective follow-up results can be used to compare the disease-free survival and overall survival of the two groups of patients with and without this method. Among the treatments with lesions, which are basic, are the ones where the results can be seen in the short term and where the protocol can be adjusted at any time. On the contrary, the treatment without foci is not visible in the near future, and in a sense is blind treatment. We should use the experience gained from “treatment with foci” to guide “treatment without foci”. For example, if preoperative neoadjuvant therapy is effective, postoperative adjuvant therapy can be administered intact with this regimen; if preoperative therapy is ineffective, no drugs in this regimen should be repeated postoperatively. Again, for example, a regimen that rescues a patient who has already achieved CR should be used directly as consolidation therapy. Although it may be resistant to repeat a regimen all the time, to activate a new regimen after reaching CR would be to fall back into blind treatment with unknown efficacy.